JP6659546B2 - 生細胞内への分子の送達のための組成物および方法 - Google Patents

生細胞内への分子の送達のための組成物および方法 Download PDF

Info

Publication number
JP6659546B2
JP6659546B2 JP2016540943A JP2016540943A JP6659546B2 JP 6659546 B2 JP6659546 B2 JP 6659546B2 JP 2016540943 A JP2016540943 A JP 2016540943A JP 2016540943 A JP2016540943 A JP 2016540943A JP 6659546 B2 JP6659546 B2 JP 6659546B2
Authority
JP
Japan
Prior art keywords
cells
cell
dtat
compound
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016540943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530303A (ja
JP2016530303A5 (https=
Inventor
ジャン−フィリップ ピロア,
ジャン−フィリップ ピロア,
Original Assignee
ザ テキサス エー アンド エム ユニバーシティ システム
ザ テキサス エー アンド エム ユニバーシティ システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ テキサス エー アンド エム ユニバーシティ システム, ザ テキサス エー アンド エム ユニバーシティ システム filed Critical ザ テキサス エー アンド エム ユニバーシティ システム
Publication of JP2016530303A publication Critical patent/JP2016530303A/ja
Publication of JP2016530303A5 publication Critical patent/JP2016530303A5/ja
Application granted granted Critical
Publication of JP6659546B2 publication Critical patent/JP6659546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016540943A 2013-09-10 2014-09-10 生細胞内への分子の送達のための組成物および方法 Active JP6659546B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361876006P 2013-09-10 2013-09-10
US61/876,006 2013-09-10
PCT/US2014/055021 WO2015038662A1 (en) 2013-09-10 2014-09-10 Compositions and methods for the delivery of molecules into live cells

Publications (3)

Publication Number Publication Date
JP2016530303A JP2016530303A (ja) 2016-09-29
JP2016530303A5 JP2016530303A5 (https=) 2017-10-19
JP6659546B2 true JP6659546B2 (ja) 2020-03-04

Family

ID=52666235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540943A Active JP6659546B2 (ja) 2013-09-10 2014-09-10 生細胞内への分子の送達のための組成物および方法

Country Status (7)

Country Link
US (2) US9662404B2 (https=)
EP (1) EP3043811B1 (https=)
JP (1) JP6659546B2 (https=)
AU (1) AU2014318839B2 (https=)
CA (1) CA2923664C (https=)
ES (1) ES2794599T3 (https=)
WO (1) WO2015038662A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2981716C (en) 2015-04-10 2022-04-12 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
FR3048698B1 (fr) 2016-03-11 2021-03-05 Univ Claude Bernard Lyon Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3
CN110291100B (zh) * 2016-10-12 2024-06-11 费尔丹生物公司 用于将多肽负荷从细胞外空间递送至靶真核细胞的胞质溶胶和/或细胞核的合理设计的合成肽穿梭剂,其用途、与其相关的方法和试剂盒
US11629170B2 (en) 2016-10-12 2023-04-18 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
EP3604520A4 (en) * 2017-03-22 2020-12-16 Kyoto University PEPTIDE FOR CYTOSOLIC ADMINISTRATION
US11821003B2 (en) 2017-08-14 2023-11-21 Sanford Burnham Prebys Medical Discovery Institute Cardiogenic mesoderm formation regulators
WO2020091535A1 (ko) * 2018-11-02 2020-05-07 순천향대학교 산학협력단 점막 투과 촉진용 펩타이드 및 이를 포함하는 조성물
JP2022512977A (ja) 2018-11-08 2022-02-07 サメイション バイオ, インコーポレイテッド ミニヌクレオソームコアタンパク質及び核酸送達における使用
KR102201154B1 (ko) * 2019-03-26 2021-01-12 가천대학교 산학협력단 폴리글루타메이트-TAT-Cre 융합 단백질의 제조방법
CA3040645A1 (en) 2019-04-18 2020-10-18 Feldan Bio Inc. Peptide-based non-proteinaceous cargo delivery
AU2021254697A1 (en) 2020-04-13 2022-11-10 Summation Bio Inc. Modified mini-nucleosome core proteins and use in nucleic acid delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
AU2006325030B2 (en) 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
EP2224940A1 (en) * 2007-11-30 2010-09-08 Cytomatrix PTY LTD Methods of inducing pluripotency involving oct4 protein
WO2010059806A2 (en) * 2008-11-20 2010-05-27 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells without the use of viral vectors
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US20120128655A1 (en) * 2009-04-03 2012-05-24 The Mclean Hospital Corporation Induced pluripotent stem cells
EP4321168A3 (en) * 2010-07-13 2024-04-24 Yale University, Inc. Environmentally sensitive compositions
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof

Also Published As

Publication number Publication date
JP2016530303A (ja) 2016-09-29
US20150099690A1 (en) 2015-04-09
CA2923664A1 (en) 2015-03-19
CA2923664C (en) 2023-05-02
WO2015038662A1 (en) 2015-03-19
US20170258933A1 (en) 2017-09-14
ES2794599T3 (es) 2020-11-18
US9662404B2 (en) 2017-05-30
EP3043811A4 (en) 2017-09-20
AU2014318839B2 (en) 2019-12-05
EP3043811B1 (en) 2020-03-25
EP3043811A1 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
JP6659546B2 (ja) 生細胞内への分子の送達のための組成物および方法
AU2014318839A1 (en) Compositions and methods for the delivery of molecules into live cells
Lundin et al. Distinct uptake routes of cell-penetrating peptide conjugates
Fischer et al. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides
EP1991560B1 (en) Peptide having cell membrane penetrating activity
Takayama et al. Enhanced intracellular delivery using arginine-rich peptides by the addition of penetration accelerating sequences (Pas)
JP6517692B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
Mäger et al. Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay
AU2017201163A1 (en) Method of determining, identifying or isolating cell-penetrating peptides
CN102811744A (zh) 用于改善基因调节化合物的递送的化学修饰的细胞渗透性肽
Buyanova et al. Discovery of a cyclic cell-penetrating peptide with improved endosomal escape and cytosolic delivery efficiency
KR101695792B1 (ko) 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
JP6617930B2 (ja) 細胞質送達ペプチド
Doh Validation of heterodimeric TAT-NLS peptide as a gene delivery enhancer
JPWO2007132555A1 (ja) 細胞膜透過性ペプチドと細胞内におけるその使用
US20030113819A1 (en) Carrier peptide and method for delivery of molecules into cells
EP4297794A2 (en) Cellular uptake of large biomolecules enabled by cell-surface-reactive cell-penetrating peptide additives
KR20090122769A (ko) 세포내로 단백질을 전달하는 방법 및 이를 위한 펩타이드
Najjar et al. An L-to D-amino acid conversion in the cell penetrating peptide dfTAT influences proteolytic stability, endocytic uptake, and endosomal escape
Yokoo Peptide and Protein Delivery
US20240400622A1 (en) Genetically encoded voltage indicators and uses thereof
US20040132970A1 (en) Dermaseptin-derived peptides and their use in delivery systems
Najjar Identifying and Characterizing Molecular Parameters that Modulate the Endosomal Escape of Cationic Cell-Penetrating Peptides: A Structure Activity Approach
Howard II Altering Histone Dynamics in vitro and in vivo
Erazo Cytosolic Delivery of Proteins, Peptides and Cell-Impermeable Small Molecules Into Live Cells Utilizing Virus-Inspired Multivalent Cell-Penetrating Peptides: Principles and Mechanisms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200206

R150 Certificate of patent or registration of utility model

Ref document number: 6659546

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250